GlassScriptPhysician profile
Priya Varghese
NPI 1124671649
$1,615.01
in general payments reported to CMS, 2019-2025
15 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $129 · 2023: $602 · 2024: $541 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $288.47 | 2024-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $237.28 | 2023-2025 | Ocaliva |
| Abbvie INC. | $164.53 | 2023-2024 | Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $145.25 | 2023 | Zeposia |
| Janssen Biotech, INC. | $139.44 | 2025 | Tremfya |
| Gilead Sciences, INC. | $113.40 | 2024 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $110.17 | 2022 | |
| Alexion Pharmaceuticals, INC. | $105.34 | 2024 | |
| Medtronic, INC. | $96.42 | 2023 | Barrx |
| Janssen Scientific Affairs, LLC | $92.07 | 2023 | Stelara |
| Celltrion USA INC. | $35.78 | 2025 | Vegzelma |
| Boston Scientific Corporation | $25.21 | 2023 | Resolution 360 Clip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.85 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $19.28 | 2025 | Entyvio |
| Edwards Lifesciences Corporation | $18.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.